JP2022502062A5 - - Google Patents

Info

Publication number
JP2022502062A5
JP2022502062A5 JP2021517817A JP2021517817A JP2022502062A5 JP 2022502062 A5 JP2022502062 A5 JP 2022502062A5 JP 2021517817 A JP2021517817 A JP 2021517817A JP 2021517817 A JP2021517817 A JP 2021517817A JP 2022502062 A5 JP2022502062 A5 JP 2022502062A5
Authority
JP
Japan
Prior art keywords
aon
seq
fana
composition according
modified nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021517817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502062A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/053033 external-priority patent/WO2020069044A1/en
Publication of JP2022502062A publication Critical patent/JP2022502062A/ja
Publication of JP2022502062A5 publication Critical patent/JP2022502062A5/ja
Pending legal-status Critical Current

Links

JP2021517817A 2018-09-26 2019-09-25 ２’ｆａｎａ修飾ｆｏｘｐ３アンチセンスオリゴヌクレオチドおよびその使用方法 Pending JP2022502062A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862737061P 2018-09-26 2018-09-26
US62/737,061 2018-09-26
US201862739001P 2018-09-28 2018-09-28
US62/739,001 2018-09-28
PCT/US2019/053033 WO2020069044A1 (en) 2018-09-26 2019-09-25 2' fana modified foxp3 antisense oligonucleotides and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2022502062A JP2022502062A (ja) 2022-01-11
JP2022502062A5 true JP2022502062A5 (enExample) 2022-10-04

Family

ID=69953290

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021517817A Pending JP2022502062A (ja) 2018-09-26 2019-09-25 ２’ｆａｎａ修飾ｆｏｘｐ３アンチセンスオリゴヌクレオチドおよびその使用方法

Country Status (7)

Country Link
US (1) US20210340536A1 (enExample)
EP (1) EP3856919A4 (enExample)
JP (1) JP2022502062A (enExample)
CN (1) CN112969799A (enExample)
AU (1) AU2019347849B2 (enExample)
CA (1) CA3112809A1 (enExample)
WO (1) WO2020069044A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202028222A (zh) * 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
EP3845646A1 (en) 2019-12-30 2021-07-07 Secarna Pharmaceuticals GmbH & Co. KG Modified antisense oligonucleotide for inhibition of foxp3 expression
WO2023235838A2 (en) * 2022-06-02 2023-12-07 Skyhawk Therapeutics, Inc. Rna-targeting splicing modifiers for treatment of foxp3-associated conditions and diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE346918T1 (de) * 1998-06-19 2006-12-15 Univ Mcgill Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide
AU4031700A (en) * 1999-04-06 2000-11-02 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation,allergy(ies) and surfactant depletion
CA2419563C (en) * 2000-09-06 2018-03-20 Mcgill University Chimeric antisense of arabinofuranose analogue and deoxyribose nucleotides
DK1470144T3 (da) * 2002-02-01 2009-04-06 Univ Mcgill Oligonukleotider omfattende alternerende segmenter og anvendelser deraf
CA2652539A1 (en) * 2006-05-19 2007-11-29 Topigen Pharmaceuticals Inc. Oligonucleotides affecting expression of phosphodiesterases
WO2008066784A2 (en) * 2006-11-27 2008-06-05 Ludwig Institute For Cancer Research Expression of foxp3 by cancer cells
US20100310635A1 (en) * 2007-04-25 2010-12-09 Engin Ozkaynak Compositions and Methods for Regulating T-Cell Activity
EP2285961A4 (en) * 2008-05-15 2012-10-17 Topigen Pharmaceuticals Inc OLIGONUCLEOTIDES FOR THE TREATMENT OF INFLAMMATION AND NEOPLASTIC CELL REPRODUCTION
WO2010048673A1 (en) * 2008-10-30 2010-05-06 Murdoch Childrens Research Institute Modulation of cellular differentiation and uses therefor
WO2010065671A2 (en) * 2008-12-04 2010-06-10 Curna, Inc. Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
KR20160027968A (ko) * 2013-06-07 2016-03-10 라나 테라퓨틱스, 인크. Ｆｏｘｐ3 발현을 조절하기 위한 조성물 및 방법
WO2017181026A1 (en) * 2016-04-15 2017-10-19 Translate Bio Ma, Inc. Selective modulation of foxp3 expression
US20200030361A1 (en) * 2016-09-23 2020-01-30 City Of Hope Oligonucleotides containing 2'-deoxy-2'fluoro-beta-d-arabinose nucleic acid (2'-fana) for treatment and diagnosis of retroviral diseases
FR3058061A1 (fr) * 2016-10-27 2018-05-04 Selexel Nouvelle utilisation d'oligonucleotides double brin

Similar Documents

Publication Publication Date Title
US11872286B2 (en) Compositions and methods for delivery of nucleic acids to cells
JP2023067871A (ja) 癌の免疫療法
US7989608B2 (en) Immunomodulatory agents and methods of use
CA3176812A1 (en) Engineered immunostimulatory bacterial strains and uses thereof
KR20210145213A (ko) Kras 관련 질환 또는 장애를 치료하기 위한 조성물 및 방법
IL270415B1 (en) Materials and methods for engineering cells and uses thereof in immuno-oncology
CN113813386A (zh) 组合肿瘤免疫疗法
KR20230117174A (ko) 핵산을 세포에 전달하기 위한 조성물 및 방법
US20230265214A1 (en) Compositions and methods for delivery of nucleic acids to cells
US20240010977A1 (en) Methods for enhancing therapeutic efficacy of isolated cells for cell therapy
IL299855A (en) Inhibitors of line1 and uses thereof
US20210380978A1 (en) The long non-coding RNA INCA1 and Homo sapiens heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) as therapeutic targets for immunotherapy
KR102858467B1 (ko) 면역세포의 면역조절 유전자의 활성 조절을 위한 조성물 및 그 용도
Liu et al. Biological response modifier in cancer immunotherapy
JP2023073256A (ja) ベータカテニン発現を減少させて免疫療法を強化する
JP2025504882A (ja) Ｒｎａによるｓｕｖ３９ｈ１発現の調節
JP2008532520A (ja) Ｔｏｌｌ様受容体８のシグナル伝達によるｃｄ４＋調節性ｔ細胞の抑制機能の直接的な反転
WO2023234297A1 (ja) がんを処置するための組成物
US20210155928A1 (en) Rna-aided immunotherapeutics